Oncternal Therapeutics announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board. Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor, ONCT-534, which is currently under investigation in an ongoing Phase 1/2 clinical study, ONCT-534-101.Smith is Director of the Genitourinary Oncology Program at Massachusetts General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONCT:
- Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics doses first patient in ONCT-534 study
- Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Oncternal Therapeutics announces Prostate Cancer Scientific Advisory Board